da-8159 and Renal-Insufficiency

Udenafil is a phosphodiesterase-5 inhibitor used to treat erectile dysfunction. Although udenafil is not predominantly eliminated by the kidney, renal impairment can alter its secretion/transport pathways. Drug pharmacokinetics and safety must therefore be assessed in subjects with a renal impairment. We investigated the effects of impaired renal function on the pharmacokinetics and safety of a single 100-mg oral dose of udenafil in a single-dose, open-label, parallel-group study of 31 subjects. Cockcroft-Gault creatinine clearance was used to stratify these subjects into healthy controls (>80 mL·min

Topics: Administration, Oral; Adult; Aged; Area Under Curve; Female; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Pyrimidines; Renal Insufficiency; Sulfonamides; Young Adult